1 / 47

Syncope

Syncope. The only difference between syncope and sudden death is that in one you wake up. 1. UHN/MSH AIMGP Seminar 2007 Yash Patel. 1 Engel GL. Psychologic stress, vasodepressor syncope, and sudden death. Ann Intern Med 1978; 89: 403-412. References.

dannyy
Download Presentation

Syncope

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Syncope The only difference between syncope and sudden death is that in one you wake up.1 UHN/MSH AIMGP Seminar 2007 Yash Patel 1 Engel GL. Psychologic stress, vasodepressor syncope, and sudden death. Ann Intern Med 1978; 89: 403-412.

  2. References • Neurocardiogenic Syncope. New England Journal of Medicine 10 March 2005. 352(10): 1004-1010. • Guidelines on Management of Syncope – Update 2004. European Heart Journal 25: 2054-2072. • Vasovagal Syncope. Ann Intern Med Nov 7 2002; 133(9):714-725. • Incidence and Prognosis of Syncope.NEJM 347(12):878-85. Sept 2002. • Primary Care:Syncope.NEJM 343(25):1856-1862. Dec 2000. • AHA Statement on Evaluation of Syncope. Circulation 113:316-327. Jan 2006.

  3. Outline 1. Objectives 2. Definitions 3. Differential diagnosis 4. Approach 5. Treatment 6. Extra material

  4. Objectives • Learn to distinguish syncope from other “non-syncopal” conditions that lead to transient loss of consciousness • Develop an approach to the assessment of patients with syncope • How to risk stratify patients with syncope • When to hospitalize patients with syncope

  5. Case 1 • 35 Woman • Unwitnessed loss of consciousness (1st. Event) • No palpitations or preceding symptoms • PMH: Hypothyroidism on replacement • Exam normal • No sequelae • No injuries IS THIS SYNCOPE? WHAT IS SYNCOPE?

  6. Some Definitions • Syncope: sudden, transient loss of consciousness and postural tone with spontaneous recovery without therapeutic intervention • Presyncope: no actual loss of consciousness • Vertigo: Dizziness accompanied by a sense of motion • Drop attacks: spontaneous falls while standing or walking without LOC

  7. Syncope: Precipitant: pain, exercise, micturition, defecation, anxiety Preceding sx: sweating and nausea Event: LOC usually <5 min Followed by: prompt recovery Seizure: Preceding sx: aura, jacksonian march Event: clonic or myoclinic jerks, LOC >5 min, incontinence Followed by: slowness, neurological deficits, postictal paresis Is it Syncope or Seizure?

  8. Epidemiology of Syncope • Population based incidence (Framingham): Men 3% per yr. Women 3.5% per yr. • It increases with age: 35 - 44 y/o 0.7% per yr. > 75 y/o 6% per yr.

  9. Case 1 • 35 Woman • Unwitnessed loss of consciousness (1st. Event) • No palpitations or preceding symptoms • PMH: Hypothyroidism on replacement • Exam normal • No sequelae • No injuries IS THIS SYNCOPE? YES, THIS WAS PROBABLY A SYNCOPAL EVENT REMEMBER SYNCOPE IS A SYMPTOM NOT A DIAGNOSIS

  10. Case 2 • 70 Woman • PMH: CAD - Previous MI CABG x 3 10 yr. Ago • Meds: Metoprolol, ASA, Fosinopril, recently started on clarithromycin for CAP • Witnessed syncope lasting 15 sec. • Palpitations prior to event • ECG: Inferior Q waves, no arrhythmias WHAT IS THE CAUSE OF HER SYNCOPE?

  11. Syncope: Etiology Neurally- Mediated Orthostatic Cardiac Arrhythmia Structural Cardio- Pulmonary Non- Cardio- vascular • 1 • Vasovagal • Carotid Sinus • • Situational • Cough • Post- micturition • 2 • Drug • Induced • • ANS • Failure • Primary • Secondary • 3 • Brady • Sick sinus • AV block • • Tachy • VT • SVT • Long QT Syndrome * • 4 • Aortic Stenosis • HOCM • • Pulmonary • Hypertension • 5 • Psychogenic • • Metabolic • e.g. hyper- • ventilation • Neurological 24% 11% 14% 4% 12% Unknown Cause = 34%

  12. Case 2 • 70 Woman • PMH: CAD - Previous MI CABG x 3 10 yr. Ago • Meds: Metoprolol, ASA, Fosinopril, recently started on clarithromycin for CAP • Witnessed syncope lasting 15 sec. • Palpitations prior to event • ECG: Inferior Q waves, no arrhythmias WHAT IS THE APPROACH TO EVALUATING SOMEONE WITH SYNCOPE?

  13. Approach 1. Hx, Physical and ECG form core workup (yields diagnosis in ~ 50 % of cases) 2. Cardiac causes carry a worse prognosis and should be excluded first 3. Exertional syncope or existing heart disease predicts worse outcomes and warrants more intense investigation 4. In the elderly think of polypharmacy

  14. History: focus on... • Precipitating Factors • exertion, position, neck or arm movement, specific activities (urination, defecation) and stressful situations • Associated Symptoms: • Nausea, diaphoresis, blurred vision - vasovagal • Diarrhea, Vx, GI bleed - volume contraction • Prodromal aura, incontinence - seizure • Medications: • side effects, overdose, interactions • antiHTN, Digoxin, diuretics, antibiotics • Family Hx: Long QT, WPW, HOCM, CAD, Brugada Syndrome

  15. Physical Exam: focus on... • Vitals: Orthostatic, BP in both arms • CSM (avoid if carotid bruits present) • Cardiac exam • Neurologic exam • Misc: Pulses, bruits, OB in stool

  16. Case 2 • 70 Woman • PMH: CAD - Previous MI CABG x 3 10 yr. Ago • Meds: Metoprolol, ASA, Fosinopril, recently started on clarithromycin for CAP • Witnessed syncope lasting 15 sec. • Palpitations prior to event • ECG: Inferior Q waves, no arrhythmias SHOULD SHE BE ADMITTED TO HOSPITAL? WHAT INVESTIGATIONS ARE INDICATED?

  17. When to Hospitalize? 1. For Investigation: structural heart disease, arrhythmias or ischemia (palpitations or chest pain), or abnormal ECG 2. For Treatment: obstructive HD, severe orthostasis, or adverse drug reactions 3. Consider in all patients with injury following syncope

  18. Investigations for Suspected Cardiac Syncope • Guided by history, physical and clinical suspicion (ie/risk factors, age >60) • Echo - abnormalities found in 5-10 % but these may not relate to sx • Stress testing if ischemic arrhythmia suspected • Prolonged ECG recording • Electrophysiologic testing • If above testing is negative and syncope recurrent, evaluate for neurally mediated syncope

  19. ECG Features Suggesting Arrhythmic Etiology • Bifasicular block • Intraventricular conduction abn (QRS>.12) • Mobitz II AV block • Sinus brady, sinus block or sinus pause >3 sec in absence of negative chronotropes • Pre-excited QRS • Prolonged QT • Brugada Syndrome:RBBB and ST elevation V1-V3 • Neg T waves in R precordial leads, epsilon waves and ventricular late potentials (ARVD) • Q waves

  20. Electrocardiographic Monitoring “ECG monitoring is unlikely to be helpful in patients who do not have clinical or ECG features suggestion an arrhythmic syncope and therefore should not be performed”

  21. Electrocardiographic Monitoring • In hospital monitoring if high risk • Holter monitoring • True + (arrhythmias with sx) ~ 4% of tests • True - (sx with no arrhythmia) ~ 17% of tests • Loop recording for longer monitoring • External if inter-symptom interval <4 wks • Consider EPS in anyone with structural heart disease with a non-diagnostic Holter

  22. Case 3 • 82 Man • PMH: HTN, BPH, Glaucoma, COPD, Depression • Meds: Diltiazem, ASA, Salbutamol, Ipratropium, Prazosin, Paroxetine, Tyl #3, Omeprazole • Syncope while urinating in early AM, shortly after rising • Trauma to forehead from episode YOUR DIAGNOSIS IS NEURALLY-MEDIATED SITUATIONAL SYNCOPE WHAT INVESTIGATIONS DOES HE NEED?

  23. Investigations for Suspected Neurally Mediated Syncope • The majority of patient with single or rare episodes do not require confirmatory tests • Investigations in patients without suspected heart disease and recurrent or severe syncope: • Tilt testing • Carotid massage • Prolonged ECG monitoring

  24. Case 3 • 82 Man • PMH: HTN, BPH, Glaucoma, COPD, Depression • Meds: Diltiazem, ASA, Salbutamol, Ipratropium, Prazosin, Paroxetine, Tyl #3, Omeprazole • Syncope while urinating in early AM, shortly after rising • Trauma to forehead from episode • Case 1 • 35 Woman • Unwitnessed loss of consciousness (1st. Event) • No palpitations or preceding symptoms • PMH: Hypothyroidism on replacement • Exam normal • No sequelae • No injuries • Case 2 • 70 Woman • PMH: CAD - Previous MI CABG x 3 10 yr. Ago • Meds: Metoprolol, ASA, Fosinopril, recently started on clarithromycin for CAP • Witnessed syncope lasting 15s • Palpitations prior to event • ECG: Inferior Q waves, no arrhythmias WHAT IS THE PROGNOSIS FOR EACH OF THESE PATIENTS WITH SYNCOPE?

  25. Risk Stratification and Prognosis in Syncope • Structural heart disease is the most important predictor of mortality and sudden death in patients with syncope • Poor Prognosis • Structural heart disease • Excellent Prognosis • Young, healthy, normal ECG • Neurally-mediated syncope • Orthostatic hypotension • Unexplained syncope

  26. Prognosis in Syncope(from Framingham database) EtiologyTotal Mortality 1yr5yr Cardiac 15% 40% Noncardiac Neurologic 5% 30% Vasovagal/Others 2% 15% Unknown 5% 25% Controls w/o syncope 2% 15% NEJM 2002;347:878

  27. Summary • Syncope is a common symptom • History/Physical can establish a diagnosis in 50% of cases • The approach involves risk assessment for the presence of cardiac disease • Investigations and Treatment are tailored to the suspected etiologic cause of syncope

  28. Extras... • Driving after syncope • Treatment of syncope • Mechanism of Vasovagal syncope • Tilt-table testing • Neurologic evaluation • Psychiatric evaluation

  29. Driving and Syncope

  30. Driving and Syncope • Physicians are obliged to disclose risk of driving to patients and advise them not to drive • 7 provinces (including Ontario) and all territories have mandatory reporting legislation

  31. Syncope and Driving • Further guidelines exist for patients with arrhythmia, MI, valvular heart disease and devices • See CCS Consensus Conference 2003: Assessment of Cardiac Patients for Fitness to Drive and Fly. Canadian Journal of Cardiology, 2004, 20(13): 1313-1323.

  32. Treatment of Syncope

  33. Treatment • Identifiable arrhythmia, structural heart disease, or non-syncopal event: Rx accordingly

  34. Treatment: Neurally-Mediated • Education and reassurance usually sufficient • Additional treatment may be warranted if: • Very frequent • Unpredictable and exposes pts to trauma • It may be valuable to assess the relative contribution of cardioinhibition and vasodepression

  35. Treatment: Nonpharmacologic • Avoid trigger events • Modify or discontinue hypotensive drugs • Other • Increase fluid intake (2L water/day) • Salt supplements • Isometric leg and arm counter-pressure maneuvers • Tilt training • Compression Stockings

  36. Treatment: Drugs • Beta-blockers discouraged in 2004 ESC guidelines • Other meds with limited evidence: • Fludricortisone • Midodrine • SSRIs • Others

  37. Treatment: Devices • Permanent dual chamber pacing may have a role in: • Those with no prodrome • Failure of other therapies • Profound bradycardia or asystole during syncope • >5 attacks per year • Age >40

  38. Mechanism of Vasovagal Syncope

  39. Mechanism of Vasovagal Syncope • Bezold–Jarisch Reflex: Excessive venous pooling triggers a chain of events that culminates in vasodilatation and bradycardia (instead of the physiologic compensatory responses of vasoconstriction and tachycardia) • This in turn leads to the hypotension and loss of consciousness associated with vasovagal syncope.

  40. Common Triggers in Situational Syncope • Defecation • Micturition (especially in elderly men with BPH that wake up at night and strain to pass urine) • Heavy straining • Cough • All situations that induce valsalva => • decreased preload + • cardioinhibitory and vasodepressor reflexes produced by central baroreceptors

  41. Tilt-Table Testing

  42. Vasovagal Syncope • Test = Head Up Tilt-table testing using a provocative agent (Isoproterenol or Nitroglycerin): • Sn and Sp difficult to evaluate because of lack of gold standard • ACC has guidelines on testing (JACC 1996:28 pg 263-275)

  43. Indicated in: 1. Recurrent syncope 2. Single syncopal event resulting in injury or occurring in high risk setting 3. Where the treatment of syncope may be complicated by vasovagal symptoms Contraindicated in presence of obstructive heart disease or cerebrovascular stenosis Head-up Tilt table testing

  44. Neurologic and Psychiatric Testing

  45. Neurologic Testing • Low yield: • EEG ~ 2% • CT head ~ 4% • Doppler carotids (no studies) • The majority of positives can be identified by history: e.g. seizure events • Bottom line: only indicated if suspicion of seizure or neuro deficits present

  46. Psychiatric evaluation • Syncope can be a feature of: • Anxiety disorders: Gen anxiety or panic • Somatization • Substance abuse • These tend to occur recurrently in younger patients without heart disease • In elderly patients organic (i.e. cardiac) causes must be excluded

More Related